In today's Pharmaceutical Executive Daily, Novartis agrees to acquire Excellergy for up to $2 billion to advance a ...
While they may be linked, the administration’s DTC drug coupon site is not necessarily the entirety of its MFN efforts. With ...
Learn how CareTria's integrated, automated platform streamlines therapy initiation and increases patient conversion rates.
Kresladi becomes the first FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2, and ...
Yerem Yeghiazarians, MD, discusses the importance of understanding why certain cells (like cancer cells) can survive in situations that would kill other healthy cells.
James N. Arvesen is president of the consulting firm Strategic Solutions and Services, Inc.
In today's Pharmaceutical Executive Daily, the Trump administration misses a statutory deadline to nominate a permanent CDC ...
The White House postponed naming a permanent CDC director as the Trump administration navigates competing political pressures ...
FDA accelerated approval positions Avlayah as the first therapy engineered to cross the blood–brain barrier for MPS ...
Arthur G. Cook is Principal, ZS Associates.
In today's Pharmaceutical Executive Daily, the FDA issues a warning letter to ImmunityBio over misleading promotional claims ...
High discontinuation—up to 70% stopping within one year—raises payer concerns about cost without durable health or downstream ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results